Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia.

This editorial describes the current status of FLT3 inhibitors in the treatment of AML and reviews a retrospective study of single institution data for use of FLT3 inhibitors with both intensive and low intensity treatment of AML. For patients who received low intensity regimens, there was benefit to the combined inclusion of FLT3 inhibitor and venetoclax in triple drug regimens, as well as improved outcomes with allogeneic transplant for all FLT3 mutated patients.